These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 22402204)

  • 1. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
    Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
    Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
    Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
    Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
    Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
    Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
    Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
    PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
    J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N; Kim E
    Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.
    Kinkel RP; Dontchev M; Kollman C; Skaramagas TT; O'Connor PW; Simon JH;
    Arch Neurol; 2012 Feb; 69(2):183-90. PubMed ID: 21987393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
    Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
    J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.